OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
October 05, 2006
SAFC, the custom manufacturing group of Sigma-Aldrich Corporation, announced at CPhI Worldwide that it will invest $16 million to expand its CGMP protein-purification capacity to meet increased market demand for therapeutic proteins from plant- and animal-sourced starting materials.
Paris (Oct. 3)-In gearing up for opportunities in the generic drug market, Codexis, which specializes in biocatalysis for pharmaceutical chemical development, is expanding into direct sale of pharmaceutical intermediates with the receipt of its first commercial orders from generic drug manufacturers for ATS-8, a chemical intermediate in atorvastatin, the API in Pfizer's top-selling drug ?Lipitor.?
October 03, 2006
As single-enantiomer drugs dominate the pharmaceutical market (1), custom manufacturers and technology providers are developing novel routes using biocatalysis and chemocatalysis, alone and combined, to improve enantioselectivity, yield, reaction conditions, and the economics of manufacture.
Merck's new supply strategy involves combining internal and external manufacturing.
Increasing costs for Indian-based CMOs may be reducing their total cost of ownership advantage.
As the pharmaceutical industry gathers for the 2006 installment of CPhI Worldwide, the annual exhibition of ingredient producers, custom manufacturers, and contract service providers, it faces an expanding number of choices for connecting with suppliers.